NFIB and glioblastoma: Identification of blood-brain barrier permeable drugs that induce NFIB expression in GBM cells, together with the identification of the GBM genotypes in which NFIB has a tumour-suppressive effect, may define a novel therapeutic strategy to augment the management of this almost uniformly fatal disease [72].